NIMOTOP - CAP 30MG 30 MG
NIMODIPINE : 30 MG · DIN 02155923 · BAYER INC
Health Canada status: CANCELLED POST MARKET
What is NIMOTOP - CAP 30MG?
NIMOTOP - CAP 30MG 30 MG contains NIMODIPINE : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02155923, held by BAYER INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 06-Aug-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NIMOTOP - CAP 30MG used for?
Adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial aneurysm.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02155923 |
|---|---|
| Brand name | NIMOTOP - CAP 30MG |
| Generic / active ingredient | NIMODIPINE : 30 MG |
| Manufacturer | BAYER INC |
| Strength | 30 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C08CA06 NIMODIPINE |
| AHFS class | 24:28.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 06-Aug-2009 |
| Original market date | 1989-12-31 00:00:00 |
How is it administered?
60 mg (two 30 mg capsules) orally every 4 hours for 21 consecutive days, starting within 4 days of SAH diagnosis. Reduce to 30 mg every 4 hours for hepatic insufficiency.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store in original foil package at 25°C (excursions 15-30°C). Protect from light and freezing.
How is it supplied?
Individually packed in foil and supplied in strips of 100 capsules per carton.
Contraindications
Hypersensitivity to nimodipine; concomitant use with phenobarbital, phenytoin, carbamazepine, or rifampin as they significantly reduce efficacy.
Warnings and precautions
DO NOT INJECT capsule contents (fatalities reported). Caution in cerebral edema or raised intracranial pressure. Monitor blood pressure; hypotension may occur.
What can be used instead?
Other Canadian products sharing ATC code C08CA06 NIMODIPINE. 1 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NIMOTOP | 30 MG | TABLET | LABORATOIRE X.0 | MARKETED | DIN 02325926 |
| NIMOTOP CAP 30MG | 30 MG | CAPSULE | MILES CANADA INC. - PHARMACEUTICAL DIVISION | CANCELLED POST MARKET | DIN 00596442 |
| NIMOTOP I.V.-0.2MG/ML | .2 MG | LIQUID | BAYER INC | CANCELLED POST MARKET | DIN 02155915 |
| NIMOTOP IV 0.2MG/ML | 0.2 MG | LIQUID | MILES CANADA INC. - PHARMACEUTICAL DIVISION | CANCELLED POST MARKET | DIN 01927124 |
Who else supplies NIMODIPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NIMODIPINE appears in 12 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.